IFNA2 and neoplasm: Taken together, these data indicate that a CD38-directed AttenukineTM may deliver robust anti-tumor activity by leveraging both tumor- and immune-directed effects of attenuated IFNα, without eliciting systemic IFNα-related toxicities.